A phase 1, open-label, dose escalation study of the safety and tolerability of ANK-101 in advanced solid tumors
Publication Title
SITC Annual Meeting; November 6-10; Houston, TX. 2024;12(Suppl 2): 677
Document Type
Abstract
Publication Date
11-1-2024
Keywords
oregon; chiles
Area of Special Interest
Cancer
Specialty/Research Institute
Oncology
Comments
Park JC, Butler MO, Curti BD, Iodice G, Pastor DM, Elassal J, Kaufman HL, Kirkwood JM.